강스템바이오텍

217730KOSDAQ

43.5 / 100

Reference Date: 2026-10-23

Financial Score14.0 / 40

News Sentiment12.5 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 12.5% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Kansstem Biotech, established in 2010, specializes in developing and manufacturing stem cell therapies, with core businesses in stem cell treatments and cosmetics. The stem cell division focuses on therapies for conditions like atopic dermatitis and rheumatoid arthritis, while the cosmetics division sells stem cell-derived products through online channels. The company also develops new drugs based on exosome technology for wound healing and hair loss.

Number of Employees

172people

Average Salary

57.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

2.57Industry Average 1.200.0Point

2.1x industry avg (risky)

ROE

-18.65Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

5.98Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼46.5% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲7.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -29.2% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (15%, downtrend)

Current 1,890Won52-week high 4,61552-week low 1,397

1-month return1.0Point

1m -12.50% (falling)

Volume trend5.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral기업설명회(IR)개최2026-09-30